HC Wainwright Issues Positive Forecast for Avalo Therapeutics (NASDAQ:AVTX) Stock Price

Avalo Therapeutics (NASDAQ:AVTX) had its price objective upped by equities research analysts at HC Wainwright from $25.00 to $40.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 197.40% from the stock’s previous close.

Other research analysts also recently issued research reports about the company. BTIG Research restated a “buy” rating and issued a $40.00 price objective on shares of Avalo Therapeutics in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Friday, January 9th. Mizuho raised shares of Avalo Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Finally, Guggenheim started coverage on shares of Avalo Therapeutics in a research report on Monday, February 2nd. They set a “buy” rating and a $50.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $42.25.

Avalo Therapeutics Stock Down 0.4%

AVTX stock opened at $13.45 on Wednesday. The firm has a market cap of $248.96 million, a PE ratio of -2.35 and a beta of 0.84. The business has a 50 day moving average of $15.57 and a 200-day moving average of $15.78. Avalo Therapeutics has a 12-month low of $3.39 and a 12-month high of $20.72.

Insiders Place Their Bets

In other Avalo Therapeutics news, insider Mittie Doyle sold 25,492 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $16.15, for a total transaction of $411,695.80. Following the completion of the transaction, the insider directly owned 3,622 shares of the company’s stock, valued at approximately $58,495.30. This represents a 87.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.25% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. BIT Capital GmbH bought a new position in shares of Avalo Therapeutics during the 3rd quarter worth $25,000. PFS Partners LLC lifted its holdings in Avalo Therapeutics by 100.0% during the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after purchasing an additional 1,000 shares during the last quarter. Quadrature Capital Ltd purchased a new stake in Avalo Therapeutics during the second quarter valued at about $55,000. Boothbay Fund Management LLC bought a new position in Avalo Therapeutics during the second quarter worth about $56,000. Finally, Dimensional Fund Advisors LP bought a new position in Avalo Therapeutics during the third quarter worth about $143,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.